HiberCell

619 West 54th Street, 8th Floor
New York
NY
10119
United States

Tel: 212.601.2800

About HiberCell

HiberCell is a clinical-stage biotechnology company dedicated to the advancement of novel therapeutics that overcome the foundational molecular barriers that prevent patients from living longer, cancer-free lives. HiberCell’s approach utilizes AI/ML to integrate multi-omic and phenotypic profiles of tumors to generate insights that connect this information to clinical outcomes. By leveraging these data, HiberCell seeks to identify and validate the causal features of cancer that can potentially be targeted with their novel therapeutic candidates with the goal of addressing the most common causes of cancer mortality: resistance, relapse and metastasis. To that end, HiberCell is developing therapeutics that resolve the stress-mediated adaptive response that is essential for cancer cell survival.

21 articles with HiberCell

HiberCell to Present Preclinical Data from Novel GCN2 Activator and PERK Inhibitor Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

11/2/2022

HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, today announced two clinical abstract poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting taking place November 8-12, 2022 in Boston, MA.
HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366 at the 2022 Annual American Society of Clinical Oncology Meeting

5/24/2022

HiberCell announced that it will present the background and design of two clinical trials of the Company’s therapeutic candidates, odetiglucan and HC-7366, in individual poster presentations at the 2022 Annual Meeting of the American Society of Clinical Oncology, which will be held in person and virtually on June 3-7, 2022 in Chicago, Illinois.
Mersana Enters Busy Gastric Cancer Space with Orphan Drug Designation

5/19/2022

On Thursday, Mersana announced that the FDA granted an orphan drug designation to one of its lead assets, XMT-2056, which is intended to treat gastric cancer.
HiberCell Announces First Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® (pembrolizumab) in Adult Patients with Metastatic, Hormone-Refractory Breast Cancer

4/28/2022

HiberCell today announced that the first patients have been dosed in a Phase 2 clinical trial of odetiglucan plus KEYTRUDA ® (pembrolizumab) for the treatment of metastatic, hormone-refractory breast cancer in adults.
Green Lights and Setbacks: Clinical Trial Updates for Feb. 21-25

2/28/2022

The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week's clinical trial news.
HiberCell Initiates its Phase 1a/b Clinical Trial of HC-7366 in Patients with Advanced Solid Tumors

2/24/2022

HiberCell has initiated a Phase 1a/b clinical trial of HC-7366, a first-in-class selective, orally bioavailable modulator of General Control Nonderepressible 2 (GNC2) for the treatment of patients with advanced solid tumors.
Clinical Catch-Up: December 11-17

12/20/2021

It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.
HiberCell to Collaborate with Merck on Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Breast Cancer

12/14/2021

HiberCell announced a clinical trial collaboration with Merck, known as MSD outside of the United States and Canada.
Clinical Catch-Up: December 6-10

12/13/2021

There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.
HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment at ESMO Immuno-Oncology Virtual Congress 2021

12/9/2021

HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, will deliver a virtual presentation on the clinical applications of our odetiglucan therapy for patients with metastatic and late-stage cancer at the ESMO Immuno-Oncology Virtual Congress 2021, December 8-11, 2021.
BioSpace Movers & Shakers, Oct. 1

10/1/2021

Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
HiberCell Appoints Jonathan Lanfear as Chief Operating Officer

9/30/2021

HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, announced the appointment of Jonathan Lanfear as chief operating officer with a focus on leading and driving HiberCell’s emerging global reach.
HiberCell Receives Fast Track Designation from FDA for First-in-Human Studies of PERK Inhibitor (PERKi) HC-5404-FUHC-5404-FU PERKi Program is Currently in a Phase 1a Clinical Trial for the Treatment of Solid Tumors

9/8/2021

HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, announced that the U.S. Food and Drug Administration has granted the company Fast Track designation for HC-5404-FU, an orally administered PERK inhibitor for patients with solid tumors.
HiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.

8/16/2021

HiberCell announced today the acquisition of Genuity Science, Inc., a life science technology company that provides world-leading genomics and multi-omic analytics bolstered by an advanced artificial intelligence (AI) and machine learning (ML) platform to illuminate the underlying cause of cancer and other diseases.
BioSpace Movers & Shakers, July 2

7/2/2021

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
HiberCell Appoints Mark J. Mulvihill, Ph.D., Chief Scientific OfficerIndustry veteran promoted to oversee discovery of HiberCell’s scientific pipeline

6/29/2021

HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, announced the appointment of Mark J. Mulvihill, Ph.D., as Chief Scientific Officer, who brings more than 20 years of experience in drug discovery and development with a focus on small molecule therapies.
Money on the Move: May 19-25

5/26/2021

Drug development requires solid funding. Here's who's standing on higher ground this week with fresh investment dollars.
BioSpace Movers & Shakers. Dec. 4

12/4/2020

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
HiberCell Bolsters Leadership Team with Appointment of Joseph Talamo as Chief Financial Officer and Promotion of Ari Nowacek, M.D., Ph.D., to Chief Business Officer

12/2/2020

HiberCell, a biotechnology company dedicated to overcoming foundational barriers that prevent patients from living longer, cancer-free lives, announced the appointment of Joseph Talamo as chief financial officer and the promotion of Ari Nowacek, M.D., Ph.D., to chief business officer.
HiberCell Announces Acquisition of Biothera Pharmaceuticals' Imprime PGG Program

7/7/2020

- Imprime PGG, a novel immune activator, has undergone rigorous Phase II testing for the treatment of metastatic breast cancer - Biothera president and chief scientific officer, Jeremy R. Graff, Ph.D., will assume the role of chief development officer at HiberCell